A Phase 4 interventional study of ranibizumab 0.5 mg in Diabetic Retinopathy, sponsored by Novartis Pharmaceuticals. Completed at 30 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing ranibizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Ranibizumab · Diabetic Retinopathy.
Among the 34 studies testing ranibizumab in Diabetic Retinopathy, this one is the 7th largest by enrollment, is one of 2 that started in 2015, is one of 10 in phase 4, and was the 21st registered.
779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 34 studies testing ranibizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:
Affiliated Hospital of Nantong University · Sites in China
Ages 18–80
Southeast Retina Center, Georgia · Sites in United States
Ages 18+
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 9 · Phase 4 10
First in 2006; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 57 across the 34 interventional studies. Of the 23 that completed or were terminated, 9 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
15 studies in Diabetic Retinopathy by Novartis: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 15 studies in Diabetic Retinopathy by Novartis, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2015, is one of 3 in phase 4, and was the 11th registered.
Novartis’s Diabetic Retinopathy studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing ranibizumab in Diabetic Retinopathy, from their registry updates:
Among Novartis’s 15 in Diabetic Retinopathy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to demonstrate that the change of best corrected visual acuity (BCVA) was comparable in patients treated with ranibizumab at the discretion of the investigator vs. treatment according to a standard of care scheme (pro re nata, as needed).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.
Drug: ranibizumab 0.5 mg
ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred
Drug: ranibizumab 0.5 mg
intravitreal injection
Also known as: Lucentis
Mean Average Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye From Month 1 to Study Treatment Completion (Month 12)
BCVA was assessed as letters read using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. The mean average change from baseline was defined as the difference between the average level of BCVA (ETDRS letters) over all post-baseline assessments from Month 1 to Month 12. A positive change represents an improvement in visual acuity
Time frame: Baseline, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Number of Visits
Mean number of visits during the study
Time frame: Baseline to Month 12
Number of Injections
mean number of injections in the study eye during the study
Time frame: Baseline to Month 12
Number of Treatment Free Intervals
A treatment-free interval is the interval between the first NO treatment given when the reason for NO treatment given is one of the three stability criteria and the first subsequent YES treatment given after that.
Time frame: Baseline to Month 12
Mean Change in Central Subfield Retinal Thickness (CSRT)
Evaluated by central reading center assessing OCT images
Time frame: Baseline to Month 12
Mean Change of Foveal Center Point Thickness
Evaluated by central reading center assessing OCT images
Time frame: Baseline to Month 12
Number of Participants With Change in Diabetic Retinopathy Study (DRS) Retinopathy Scale
Evaluated by central reading center scoring fundus photography
Time frame: Baseline to Month 12
a total of 135 patients were randomized and assigned in a 1:1 ratio to the treatment arms.
| Milestone | Discretion of the Investigator (DI) | Pro re Nata (PRN) |
|---|---|---|
| Started | 68 | 67 |
| Full analysis set (fas) | 67 | 66 |
| Per protocol set (pps) | 62 | 61 |
| Completed | 62 | 58 |
| Not completed | 6 | 9 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 5 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Other | 0 | 2 |
BCVA was assessed as letters read using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. The mean average change from baseline was defined as the difference between the average level of BCVA (ETDRS letters) over all post-baseline assessments from Month 1 to Month 12. A positive change represents an improvement in visual acuity
| Letters | Discretion of the Investigator (DI) | Pro re Nata (PRN) |
|---|---|---|
| Baseline (Day 1) | 67.4 ± 9.52 | 65.1 ± 9.59 |
| post baseline average over month 1 to month 12 | 73.5 ± 9.50 | 73.8 ± 7.75 |
| Visit-averaged change from baseline | 6.1 ± 6.54 | 8.6 ± 6.45 |
Mean number of visits during the study
| Visits | Discretion of the Investigator (DI) | Pro re Nata (PRN) |
|---|---|---|
| Number of Visits | 12.7 ± 1.92 | 12.9 ± 2.25 |
mean number of injections in the study eye during the study
| Injections | Discretion of the Investigator (DI) | Pro re Nata (PRN) |
|---|---|---|
| Number of Injections | 8.4 ± 2.98 | 7.8 ± 3.25 |
A treatment-free interval is the interval between the first NO treatment given when the reason for NO treatment given is one of the three stability criteria and the first subsequent YES treatment given after that.
| Intervals | Discretion of the Investigator (DI) | Pro re Nata (PRN) |
|---|---|---|
| Number of Treatment Free Intervals | 1.6 ± 0.76 | 1.7 ± 0.94 |
Evaluated by central reading center assessing OCT images
| μm | Discretion of the Investigator (DI) | Pro re Nata (PRN) |
|---|---|---|
| Baseline | 420.0 ± 114.98 | 431.0 ± 128.13 |
| Month 12 (LOCF) | 313.3 ± 61.21 | 320.6 ± 85.27 |
| Change from Baseline to Month 12 (LOCF) | -106.7 ± 109.58 | -110.4 ± 101.97 |
Evaluated by central reading center assessing OCT images
| μm | Discretion of the Investigator (DI) | Pro re Nata (PRN) |
|---|---|---|
| Baseline | 398.8 ± 144.10 | 405.0 ± 138.06 |
| Month 12 - LOCF | 273.3 ± 84.85 | 280.6 ± 105.44 |
| Change from Baseline to Month 12 (LOCF) | -125.6 ± 142.69 | -124.4 ± 113.29 |
Evaluated by central reading center scoring fundus photography
| Participants | Discretion of the Investigator (DI) | Pro re Nata (PRN) |
|---|---|---|
| > 2 steps improvement | 7 | 7 |
| 2 steps improvement | 3 | 4 |
| 1 step improvement | 6 | 1 |
| 0 steps | 38 | 34 |
| 1 step loss | 4 | 4 |
| 2 steps loss | 2 | 1 |
| > 2 steps loss | 1 | 5 |
| Missing | 6 | 10 |
Collected over From start of study treatment until month 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Discretion of the Investigator (DI) | 1/68 (1.5%) | 13/68 (19.1%) | 44/68 (64.7%) |
| Pro re Nata (PRN) | 2/67 (3%) | 22/67 (32.8%) | 43/67 (64.2%) |
| Event | Discretion of the Investigator (DI) | Pro re Nata (PRN) |
|---|---|---|
| Cardiac failureCardiac disorders | 0/68 | 2/67 |
| GastritisGastrointestinal disorders | 1/68 | 2/67 |
| Blood glucose increasedInvestigations | 0/68 | 2/67 |
| Acute kidney injuryRenal and urinary disorders | 2/68 | 0/67 |
| Angina pectorisCardiac disorders | 0/68 | 1/67 |
| Coronary artery diseaseCardiac disorders | 1/68 | 1/67 |
| Heart valve incompetenceCardiac disorders | 0/68 | 1/67 |
| CataractEye disorders | 0/68 | 1/67 |
| Eyelid function disorderEye disorders | 0/68 | 1/67 |
| Retinal detachmentEye disorders | 1/68 | 1/67 |
| Event | Discretion of the Investigator (DI) | Pro re Nata (PRN) |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 19/68 | 18/67 |
| Conjunctival haemorrhageEye disorders | 13/68 | 14/67 |
| Visual acuity reducedEye disorders | 7/68 | 8/67 |
| Intraocular pressure increasedInvestigations | 8/68 | 6/67 |
| Glycosylated haemoglobin increasedInvestigations | 5/68 | 7/67 |
| HypertensionVascular disorders | 3/68 | 7/67 |
| Eye painEye disorders | 7/68 | 4/67 |
| Foreign body sensation in eyesEye disorders | 6/68 | 1/67 |
| Vitreous haemorrhageEye disorders | 6/68 | 2/67 |
| CataractEye disorders | 2/68 | 5/67 |
Full analysis set (FAS). All patients randomized who received at least one application of study treatment and had at least one post-baseline assessment for the primary endpoint (BCVA).
| Age, Continuous(years) | Discretion of the Investigator (DI) | Pro re Nata (PRN) | Total |
|---|---|---|---|
| Mean | 62.6 ± 13.73 | 65.0 ± 10.37 | 63.8 ± 12.19 |
| Sex: Female, Male(Participants) | Discretion of the Investigator (DI) | Pro re Nata (PRN) | Total |
|---|---|---|---|
| Female | 22 | 25 | 47 |
| Male | 45 | 41 | 86 |
| Race/Ethnicity, Customized(Participants) | Discretion of the Investigator (DI) | Pro re Nata (PRN) | Total |
|---|---|---|---|
| Caucasian | 64 | 64 | 128 |
| Black | 1 | 1 | 2 |
| Asian | 0 | 1 | 1 |
| Other | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Feb 2015 to primary completion in Jun 2017, 27 months.
Results were first posted in Jan 2019, 1 year 6 months after primary completion.
Of 32 phase 4 interventional studies under Diabetic Retinopathy, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 27 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab